Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
Abstract
Purpose MEHD7945A is a novel dual-action monoclonal antibody in which each of the two antigen-binding fragments is capable of binding to EGFR and HER3 with high affinity. It is being evaluated as a potential therapy for human cancer. The purpose of these studies was to characterize the pharmacokinetics (PK) of MEHD7945A in mouse and monkey and predict its human PK and efficacious dose.Methods PK of MEHD7945A was determined in SCID beige mice and cynomolgus monkeys after administration of single intravenous doses. Human PK profiles were projected from monkey PK profiles using a species-invariant time method, and human population PK parameters were estimated using a nonlinear, two-compartment model comprising specific (target-mediated) and nonspecific clearance pathways. The antitumor efficacy in mice bearing human tumor xenografts was used in conjunction with human PK projections to estimate human efficacious doses.Results The total clearance of MEHD7945A decreased with increase in dose in both mouse and monkey. The nonspecific clearance in monkey was estimated to be 14 mL/day/kg. The predicted nonspecific clearance range in humans was 6-10 mL/day/kg. Doses of 8-12 mg/kg administered every 2 weeks in humans were predicted to achieve exposure of 300 day μg/mL per week to match the efficacious exposure observed in xenograft models.Conclusions The PK of MEHD7945A was nonlinear in mouse and monkey in the dose range tested. The nonspecific clearance in monkey was approximately twofold higher than typical humanized IgG1 antibodies. The projected human efficacious dose and dose regimen appear to be achievable in patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a retrospective population PK/PD analysis on eight targeted and cytotoxic agents with known clinical outcome, greater than 60% tumor growth inhibition in preclinical models at clinically relevant exposures was more likely to lead to responses in the clinic.
“Wong and colleagues showed that greater than 60% tumor growth inhibition in preclinical models at clinically relevant exposures was more likely to lead to responses in the clinic.78”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [78]
Cites
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,063 · see citing works
ErbB receptors and signaling pathways in cancer
Hynes, N. E., & MacDonald, G. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.12.010 · Cited by 956 · see citing works
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.
Soltoff, S. P., Carraway, K. L., Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3550 · Cited by 515 · see citing works
Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
Dirks, N. L., & Meibohm, B. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535960-000000000-00000 · Cited by 500 · see citing works
Dedrick, R. L. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059667 · Cited by 397 · see citing works
Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site
Boström, J., Yu, S., Kan, D., Appleton, B. A., Lee, C. V., Billeci, K. L., Man, W., Peale, F. V., Jr., Ross, S., Wiesmann, C., et al. (2009) · Science · doi:10.1126/science.1165480 · Cited by 372 · see citing works
Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B. E., Kalra, A. V., Paragas, V. B., Bukhalid, R. A., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 358 · see citing works
Schaefer, G., Haber, L., Crocker, L., Shia, S., Shao, L., Dowbenko, D. J., Tótpál, K., Wong, A., Lee, C. V., Stawicki, S. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341 · see citing works
Self-citationThe epidermal growth factor receptor–tyrosine kinase: A promising therapeutic target in solid tumors
Ritter, C. A., & Arteaga, C. L. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50027 · Cited by 312 · see citing works
Deng, R., Iyer, S., Theil, F.-P., Mortensen, D. L., Fielder, P. J., & Prabhu, S. (2011) · mAbs · doi:10.4161/mabs.3.1.13799 · Cited by 285 · see citing works
Targeting HER proteins in cancer therapy and the role of the non-target HER3
Hsieh, A. C., & Moasser, M. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603910 · Cited by 269 · see citing works
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation
Schoeberl, B., Faber, A. C., Li, D., Liang, M.-C., Crosby, K., Onsum, M., Burenkova, O., Pace, E., Walton, Z., Nie, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3145 · Cited by 264 · see citing works
Targeting HER1/EGFR: A molecular approach to cancer therapy
Arteaga, C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70010-4 · Cited by 250 · see citing works
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies
Mould, D. R., & Green, B. (2010) · BioDrugs · doi:10.2165/11530560-000000000-00000 · Cited by 207 · see citing works
The HER family and cancer: emerging molecular mechanisms and therapeutic targets
Sergina, N. V., & Moasser, M. M. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.10.002 · Cited by 154 · see citing works
Interspecies Scaling of Protein Drugs: Prediction of Clearance from Animals to Humans
Mahmood, I. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10531 · Cited by 91 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works
HER3 signaling and targeted therapy in cancer
Mishra, R., Patel, H. M., Alanazi, S., Yuan, L., & Garrett, J. T. (2018) · Oncology Reviews · doi:10.4081/oncol.2018.355 · Cited by 175 · see citing works
Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies
Kamath, A. V. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.09.004 · Cited by 158 · see citing works
Self-citationCohen, R. B. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.002 · Cited by 135 · see citing works
The future of antibodies as cancer drugs
Reichert, J. M., & Dhimolea, E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.04.006 · Cited by 124 · see citing works
Cao, Y., & Jusko, W. J. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9372-2 · Cited by 92 · see citing works
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
Aurisicchio, L., Marra, E., Roscilli, G., Mancini, R., & Ciliberto, G. (2012) · Oncotarget · doi:10.18632/oncotarget.550 · Cited by 83 · see citing works
Clinical Pharmacology and Translational Aspects of Bispecific Antibodies
Trivedi, A., Stienen, S., Zhu, M., Li, H., Yuraszeck, T., Gibbs, J., Heath, T., Loberg, R., & Kasichayanula, S. (2017) · Clinical and Translational Science · doi:10.1111/cts.12459 · Cited by 76 · see citing works
HER3/ErbB3, an emerging cancer therapeutic target
Zhang, N., Chang, Y., Rios, A. A., & An, Z. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv103 · Cited by 75 · see citing works
Worden, F. P., & Sacco, A. G. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s93720 · Cited by 50 · see citing works
Emerging drugs for head and neck cancer
Wen, Y., & Grandis, J. R. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1031653 · Cited by 48 · see citing works
Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody
Zheng, S., Moores, S. L., Jarantow, S. W., Pardinas, J. R., Chiu, M. L., Zhou, H., & Wang, W. (2016) · mAbs · doi:10.1080/19420862.2015.1136762 · Cited by 46 · see citing works
Kaumaya, P. T. P. (2020) · Future Oncology · doi:10.2217/fon-2020-0224 · Cited by 38 · see citing works
Miller, M. J., Foy, K. C., Overholser, J. P., Nahta, R., & Kaumaya, P. T. P. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956012 · Cited by 29 · see citing works
Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers
Desai, M. D., Saroya, B. S., & Lockhart, A. C. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.761972 · Cited by 28 · see citing works
Xue, J., Kong, D., Yao, Y., Yang, L., Yao, Q., Zhu, Y., Ding, Y., Yang, F., Gong, J., Shen, L., et al. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.06.015 · Cited by 25 · see citing works
Ménochet, K., Yu, H., Wang, B., Tibbitts, J., Hsu, C., Kamath, A. V., Richter, W. F., & Baumann, A. (2022) · mAbs · doi:10.1080/19420862.2022.2145997 · Cited by 25 · see citing works
Self-citationPrice, K. A. R., & Cohen, E. E. W. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.01.018 · Cited by 22 · see citing works
Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance
Temraz, S. N., Mukherji, D., & Shamseddine, A. I. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.009 · Cited by 22 · see citing works
Kaumaya, P. T. P. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1026495 · Cited by 19 · see citing works
Lee, B., Kang, S. U., Hwang, H. S., Kim, Y., Sung, E.-S., Shin, Y. S., Lim, Y. C., & Kim, C. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.02.007 · Cited by 18 · see citing works
Meneses‐Lorente, G., Friess, T., Kolm, I., Hölzlwimmer, G., Bader, S., Meille, C., Thomas, M., & Bossenmaier, B. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2697-8 · Cited by 17 · see citing works
Ovacik, A. M., Li, J., Lemper, M., Danilenko, D. M., Stagg, N. J., Mathieu, M. A., Ellerman, D. A., Gupta, V., Kalia, N., Nguy, T., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1551676 · Cited by 16 · see citing works
Self-citationDiermeier‐Daucher, S., Ortmann, O., Buchholz, S., & Brockhoff, G. (2012) · mAbs · doi:10.4161/mabs.21003 · Cited by 14 · see citing works
Ayoub, M. A., See, H. B., Seeber, R. M., Armstrong, S. P., & Pfleger, K. D. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064672 · Cited by 14 · see citing works
Xiang, H., Reyes, A. E., Eppler, S., Kelley, S. K., & Damico‐Beyer, L. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2200-3 · Cited by 12 · see citing works
Self-citationOther targeted drugs in melanoma.
González‐Cao, M., Rodon, J. A., Karachaliou, N., Sanchez, J. M., Santarpía, M., Viteri, S., Pilotto, S., Teixidó, C., Riso, A. A., & Rosell, R. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.12 · Cited by 12 · see citing works
EGF receptor family: twisting targets for improved cancer therapies
Burgess, A. W., Henis, Y. I., Hynes, N. E., Jovin, T. M., Levitzki, A., Pinkas‐Kramarski, R., & Yarden, Y. (2014) · Growth Factors · doi:10.3109/08977194.2014.896355 · Cited by 9 · see citing works
Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers
Eccles, S. A. (2012) · Frontiers in bioscience · doi:10.2741/4118 · Cited by 9 · see citing works
Campbell, N. P., Hensing, T. A., Bhayani, M. K., Shaikh, A. Y., & Brockstein, B. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1202116 · Cited by 9 · see citing works
Niu, J., Wang, W., & Ouellet, D. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2257136 · Cited by 8 · see citing works
Molecular Targeting of Growth Factor Receptor Signaling in Radiation Oncology
Huang, S., Rodemann, H. P., & Harari, P. M. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-662-49651-0_3 · Cited by 6 · see citing works
Differences in genomic profile of high-grade urothelial carcinoma according to tumor location
Park, C. K., & Cho, N. H. (2021) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.08.019 · Cited by 5 · see citing works
Yao, Q., Lee, Y., & Zhou, T. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00780-4 · Cited by 3 · see citing works
Nonclinical Development of Multi-targeting Biopharmaceuticals
Prell, R. A., Lee, D. W., Halpern, W., & Connor, A. V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00014-9 · Cited by 2 · see citing works
Use of PK / PD Knowledge in Guiding Bispecific Biologics Research and Development
Baumann, A., Prabhu, S., & Kanodia, J. (2015) · Pharmaceutical Sciences Encyclopedia · doi:10.1002/9780470571224.pse562 · Cited by 3 · see citing works
Resistance to Anticancer Antibodies: From Mechanisms to Solutions
Reslan, L., & Dumontet, C. (2013) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-1-4614-7654-2_1
Bifunctional Antibodies: Preclinical and Clinical Applications
Shuptrine, C. W., & Weiner, L. M. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8809-5_10
Characterization and Applications of Single-Domain Antibody Mimics against ErbB3
Zhou, Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/d9ay-bm10
Gu, J., McCluskey, A. J., & Ghayur, T. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch8
- Authors
- Kamath, A. V., Lu, D., Gupta, P., Jin, D., Xiang, H., Wong, A., Leddy, C., Crocker, L., Schaefer, G., Sliwkowski, M. X., & Damico-Beyer, L. A.
- Affiliations
- Genentech (US)
- Corresponding author
- Kamath, Amrita V.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2011-12-28
- Volume
- 69
- Issue
- 4
- Pages
- 1063-1069
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2022554477
- Cited by
- 41
- References
- 16
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 3 · 2017: 2 · 2016: 6 · 2015: 7 · 2014: 3 · 2013: 8 · 2012: 5
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Genentech
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- human pharmacokinetic prediction, Macaca fascicularis, SCID/beige mice, dose proportionality
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Immunoglobulin G, Macaca fascicularis, Mice, SCID, Receptor, ErbB-3, Mice, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
